GNPX News and Press, Genprex Inc. From 05/04/20

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progres...

Company provides updates on recent regulatory, clinical, operational, and business developments Fast Track Designation by FDA for Oncoprex™ in combination with osimertinib in non-small cell lung cancer emphasized Exclusive license agreement with University of Pittsburg...

Are These On Your Penny Stocks Watch List In 2020? I’m pretty sure that most people don’t think about penny stocks and analyst ratings at first. From what I’m sure many of you initially experienced, penny stocks have been known for volatile trading of “start-up&#x...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the update, Inman will lead in...

Proven executive with clinical operations expertise to guide Company’s clinical programs with gene therapies Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing tech...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which include Brent Longnecker, CEO of ...

Genprex (NASDAQ: GNPX ) appoints three new members to its Board of Directors. The new Board members include Brent Longnecker, CEO of Longnecker & Associates, Jose A. Moreno Toscano, CEO of LFB USA Inc, and William R. (“Will”) Wilson, Jr., Chairman, President and CEO ...

Board additions will enhance Company’s ability to execute on key corporate initiatives Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Catherine M. Vaczy as executive vice president and chief strategy officer and Michael T. Redman as executi...

BioNTech SE (NASDAQ: BNTX ) -16% . More news on: BioNTech SE, Mesoblast Limited, InterContinental Hotels Group PLC, Stocks on the move, , Read more ...